• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai , Aug. 10

NICHOLAS Piramal India Ltd (NPIL) said on Tuesday that it has entered into a research collaboration with the National Institute of Immunology (NII) in New Delhi.

The collaboration is an integral part of NPIL's R&D programme to discover and develop new chemical entities (NCE) in the field of inflammation, a company communiqué said.

NPIL is focusing its research efforts on the development of NCEs and New Drug Delivery Systems in therapeutic areas including cancer, diabetes and metabolic disorders, inflammation and anti-infectives.

The company's lead molecule in Oncology, P-276-00, is undergoing advanced toxicology testing and is on track to enter human clinical trials by the end of this year, the company said.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ford retires high-cost debt; Fusion launch likely in Nov

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line